Immediate Impact
3 hit
Citing Papers
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
2022 Hit
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
2021 Hit
Works of Phuong Khuu being referenced
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa
2019
Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa
2016